Nimodipine-d7

Nimodipine-d7

• CAS Number: 1246815-36-0
• UNSPSC Description: Nimodipine-d7 is the deuterium labeled Nimodipine. Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].
• Target Antigen: Autophagy; Calcium Channel; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Autophagy;Membrane Transporter/Ion Channel;Neuronal Signaling;Others
• Field of Research: Cardiovascular Disease; Cancer
• Purity: 99.35
• Solubility: DMSO : 100 mg/mL (ultrasonic;warming)
• Smiles: COCCOC(C1=C(C)NC(C)=C(C(OC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)C1C2=CC(N(=O)=O)=CC=C2)=O
• Molecular Weight: 425.48
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989).|[3] Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34(5):932-938.|[4]Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2(1):61-72.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported